Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients
Launched by SECOND AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY · Mar 30, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Temperature \> 38°C or \< 36°C;
- • 2. Heart rate \> 90 beats/min;
- • 3. Respiratory rate \> 20 breaths/min or PaCO₂ \< 32 mmHg;
- • 4. White blood cell count \> 12.0 × 10⁹/L or \< 4.0 × 10⁹/L, or \> 10% immature neutrophils;
- • 5. Initial septic shock diagnosis;
- • 6. Organ dysfunction (cardiovascular, respiratory, or ≥ 2 other organs);
- • 7. Complete clinical data.
- Exclusion Criteria:
- • 1. Cancer history;
- • 2. Chemotherapy;
- • 3. Radiotherapy;
- • 4. Incomplete data.
- • 5. Controls were free of infectious or inflammatory diseases and glucocorticoid use.
About Second Affiliated Hospital Of Wenzhou Medical University
The Second Affiliated Hospital of Wenzhou Medical University is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care. As a prominent teaching hospital, it integrates clinical practice with innovative research and education, fostering a collaborative environment for healthcare professionals. The hospital is equipped with state-of-the-art facilities and a diverse range of specialized departments, enabling it to conduct comprehensive clinical trials across various medical fields. Its mission is to enhance healthcare outcomes through rigorous scientific inquiry and to contribute to the global body of medical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wenzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported